Report of Foreign Issuer (6-k)
February 26 2018 - 9:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 26, 2018
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Election
of employee representatives to the Board of Directors of Novo Nordisk A/S
Bagsværd, 26 February 2018
– The employees of Novo
Nordisk A/S have conducted the election of employee representatives to the Board of Directors of Novo Nordisk A/S.
The following members were elected for the next four years:
As substitutes to the employee representatives to the Board of Directors
of Novo Nordisk A/S, the employees elected Anders Kaae, Karina Bonde Lenau, Jesper Thorning and Tanja Villumsen.
The new employee representatives will join the Board of Directors following
the annual general meeting of Novo Nordisk A/S, 22 March 2018. At the same event, the former employee representatives, Liselotte
Hyveled and Søren Thuesen Pedersen will withdraw from the Board of Directors.
About employee representatives
According to the Danish Companies Act, the employees in companies, which
have for the last three years employed at least 35 employees on average, have a right to elect a number of members to the board
of directors. The employee-elected board members shall represent a number that corresponds to at least half of the board members
elected by the annual general meeting. Furthermore, substitutes corresponding to the number of employee-elected board members must
be elected. The employee-elected board members act on the same terms as the board members elected by the annual general meeting,
but are elected for a four-year period.
Page 2 of 2
Novo Nordisk is
a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience
and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.
Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than
170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange
(NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Katrine Sperling
|
+45 3079 6718
|
krsp@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 786 8316
|
kiau@novonordisk.com
|
|
|
|
Investors
:
|
|
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Hanna Ögren
|
+45 3079 8519
|
haoe@novonordisk.com
|
Anders Mikkelsen
|
+45 3079 4461
|
armk@novonordisk.com
|
Christina Kjær
|
+45 3079 3009
|
cnje@novonordisk.com
|
Kasper Veje (US)
|
+1 609 235 8567
|
kpvj@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 20 / 2018
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: February 26, 2018
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024